Rocket Pharmaceuticals Announces Participation at Upcoming Conferences

November 1, 2018

NEW YORK--(BUSINESS WIRE)--Nov. 1, 2018-- Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) ("Rocket"), a leading U.S.-based multi-platform gene therapy company, announces participation at the following upcoming industry conferences:

- Evercore ISI HealthConX Conference
  - Gaurav Shah, M.D., Chief Executive Officer and President, will participate in a fireside chat on November 28, 2018, at 1:15 p.m. Eastern Time in Boston, MA
- Barclays Gene Editing & Gene Therapy Summit
  - Dr. Shah will present on November 29, 2018, at 11:15 a.m. Eastern Time in New York, NY
- American Society of Hematology 2018 Annual Meeting
  - Dr. Juan Bueren, Head of the Hematopoietic Innovative Therapies Division at CIEMAT in Spain and program principal investigator of the Phase 1/2 trial of RP-L102, will present the abstract "Advances in the Gene Therapy of Patients with Fanconi Anemia" in an oral session on December 3, 2018, at 6:30 p.m. Pacific Time in San Diego, CA. The presentation will include long-term follow up data from the first four patients treated, as presented at the 2018 Annual Congress of the European Society of Gene and Cell Therapy in October.

A live audio webcast of the Evercore ISI presentation will be available on the Investors section of the company's website, www.rocketpharma.com. A replay of the presentation will be archived on the Rocket website following the conference.

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) ("Rocket") is an emerging, clinical-stage biotechnology company focused on developing first-in-class gene therapy treatment options for rare, devastating diseases. Rocket's multi-platform development approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. Rocket's lead clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. Preclinical studies of additional bone marrow-derived disorders are ongoing and target Pyruvate Kinase Deficiency (PKD), Leukocyte Adhesion Deficiency-I (LAD-I) and Infantile Malignant Osteopetrosis (IMO). Rocket is also developing an AAV-based gene therapy program for an undisclosed rare pediatric disease. For more information about Rocket, please visit www.rocketpharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181101005623/en/

Source: Rocket Pharmaceuticals, Inc.

Claudine Prowse, Ph.D.
SVP, Corporate Strategy and IRO
Rocket Pharma, Inc.
The Empire State Building, Suite 7530
New York, NY 10118
cp@rocketpharma.com
www.rocketpharma.com
investors@rocketpharma.com